Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients

Emilio Bria, Cecilia Nistico, Federica Cuppone, Paolo Carlini, Mariangela Ciccarese, Michele Milella, Guido Natoli, Edmondo Terzoli, Francesco Cognetti, Diana Giannarelli

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. The magnitude of the survival benefit of taxanes as adjuvant chemotherapy for early breast cancer is still unclear, A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy, METHODS. All Phase III trials were considered eligible. A pooled analysis was accomplished and event-based relative risk ratios (RR) with 95% confidence intervals (95% CI) were derived. The significant differences in disease-free survival (DFS) and overall survival (OS) were explored. Magnitude outcome measures were absolute benefits and the number of patients needed to treat. A heterogeneity test was applied as well. A sensitivity analysis in 6 subpopulations was also performed. RESULTS. Nine trials designed to assess if paclitaxel or docetaxel improve survival (15,598 patients) were gathered. One of the 9 trials did not report OS results. Significant differences in favor of taxanes were seen in DFS in the overall (RR: 0.86; 95% CI, 0.81-0.90 [P

Original languageEnglish
Pages (from-to)2337-2344
Number of pages8
JournalCancer
Volume106
Issue number11
DOIs
Publication statusPublished - Jun 1 2006

Keywords

  • Adjuvant
  • Breast cancer
  • Chemotherapy paclitaxel
  • Docetaxel
  • Metaanalysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients'. Together they form a unique fingerprint.

Cite this